Novartis' Hoppenot to head Incyte

Herve Hoppenot departed as president of the Novartis Oncology business of Novartis AG (NYSE:NVS; SIX:NOVN) to become president, CEO and a director of cancer and inflammation company Incyte Corp. (NASDAQ:INCY). He succeeds Paul Friedman, who is retiring but will remain an Incyte director. Alessandro Riva, global head of Novartis Oncology development and medical affairs, will serve as interim president of Novartis Oncology. ...